Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program

Amid sliding sales for prostate cancer drug Xofigo, Bayer will bolster its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics.